Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy
- Kristian Brock (Contributor)
- Peter Hillmen (Speaker)
- Talha Munir (Contributor)
- Andy Rawstron (Contributor)
- Samuel Munoz Vicente (Contributor)
- Yates, F. (Contributor)
- Rebecca Bishop (Contributor)
Activity: Academic and Industrial events › Conference, workshop or symposium